疾病活动度对药物可及性受限国家RA治疗选择的影响
该离散选择实验纳入匈牙利、罗马尼亚和英国的148名风湿免疫科医生,评估患者疾病活动度对类风湿关节炎治疗选择的影响。结果显示,无论高或中等疾病活动度,疗效均主导治疗选择;高疾病活动度时疗效重要性从48%升至57%,患者偏好重要性从15%降至11%,经济与安全性考量无显著差异。
要点
- 疗效在高和中等疾病活动度患者中均主导RA治疗选择
- 高疾病活动度时疗效重要性从48%升至57%,患者偏好重要性从15%降至11%
- 经济与安全性考量不受疾病活动度显著影响
核心结论
- 相比高疾病活动度患者,风湿免疫科医生为中等疾病活动度患者选择治疗时愿意牺牲部分疗效以考虑患者偏好。
- 疾病活动度并未影响经济因素在治疗选择中的重要性。
研究设计与样本
- 邀请匈牙利、罗马尼亚和英国的风湿免疫科医生完成两项连续离散选择实验,分别针对高疾病活动度和中等疾病活动度的假设患者画像。
- 医生反复在两种非标签治疗选项间选择,选项在疗效、安全性、患者偏好、总药物费用和成本效果五个属性上不同。
- 采用异方差离散选择模型,通过属性水平与患者画像(二分类变量)的交互项评估医生偏好及患者画像的影响。
- 共148名风湿免疫科医生完成调查,46%为女性,平均年龄49岁,49%来自学术机构。
主要发现
- 在高和中等疾病活动度两种患者画像中,疗效均主导治疗选择,超过患者偏好、安全性和经济方面。
- 高疾病活动度相比中等疾病活动度,药物疗效重要性从48%显著增至57%。
- 高疾病活动度相比中等疾病活动度,患者偏好重要性从15%显著降至11%。
- 经济与安全性考量在两种患者画像间无显著差异。
临床怎么用
- 在药物可及性受限环境下,医生为高疾病活动度RA患者处方时应优先确保疗效,对中等疾病活动度患者可更多纳入患者偏好。
- 经济因素在两类患者治疗选择中的重要性相当,提示费用考量不因疾病活动度而弱化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the influence of disease activity of patients with rheumatoid arthritis on treatment choices of rheumatologists in countries with restricted access to expensive, innovative drugs. METHODS: Rheumatologists from Hungary, Romania and UK were invited to complete two consecutive discrete choice experiments with hypothetical drug treatments for two different patient profiles: high and moderate disease activity. Rheumatologists were asked to choose repeatedly between two unlabelled treatment options that differed in five attributes: efficacy (expected improvement and achieved disease activity state), safety (probability of serious adverse events), patient's preference (level of agreement), total medication costs and cost-effectiveness. A heteroscedastic discrete choice model using interaction terms between attribute levels and patient profiles (binary variable) was used to assess the preferences of rheumatologists towards each attribute and the influence of the patient profile. RESULTS: Overall, 148 rheumatologists completed the survey (46% females, mean age 49 years, 49% academic). For both patient profiles, efficacy dominated the treatment choice over patient's preference, safety and economic aspects. However, for patients with high compared with moderate disease activity, the importance of drug efficacy significantly increased (from 48% for moderate to 57% for high disease activity), whereas the importance of patient's preference significantly decreased (from 15% to 11%). No significant differences were observed for economic and safety considerations. CONCLUSION: Rheumatologists were willing to give up some efficacy to account for patient's preference when choosing treatments for patients with moderate compared to high disease activity. Disease activity however did not influence importance of economic aspects in treatment choices.
引用
- Hifinger M, Hiligsmann M, Ramiro S, et al. Influence of disease activity on RA treatment choices in countries with restricted access to expensive, innovative drugs: a discrete choice experiment among rheumatologists. RMD Open. 2017. PMID: 28912960. doi:10.1136/rmdopen-2017-000453
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。